The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer
|
|
- Nathan Morris
- 6 years ago
- Views:
Transcription
1 55 The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer Matthew C. Abramowitz, MD 1 Tiaynu Li, MA 2 Mark K. Buyyounouski, MD 1 Eric Ross, PhD 2 Robert G. Uzzo, MD 3 Alan Pollack, MD, PhD 1 Eric M. Horwitz, MD 1 1 Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 2 Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 3 Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Supported in part by Grants CA and CA from the National Cancer Institute and a grant from Varian Medical Systems, Palo Alto, California. We thank Dr. Gerald Hanks for his leadership in the establishment of the Fox Chase Cancer Center database for the treatment of prostate cancer reported herein and Ruth Peter for her dedication to its maintenance. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute or Varian Medical Systems. Address for reprints: Eric M. Horwitz, MD, Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA ; Fax: (215) ; eric. horwitz@fccc.edu Received June 20, 2007; revision received July 30, 2007; accepted August 2, BACKGROUND. The American Society for Therapeutic Radiology and Oncology (ASTRO) definition of biochemical failure (BF) incorporates backdating, resulting in an artificial flattening of Kaplan-Meier curves and overly favorable estimates when follow-up is short. The nadir 1 2 ng/ml (Nadir 1 2; Phoenix) definition reduces these artifacts. The objective of the current study was to compare ASTRO and Phoenix BF estimates as determinants of distant metastasis (DM), cause-specific mortality (CSM), and overall mortality (OM). METHODS. A total of 1831 patients with T1-4N0M0 prostate cancer were treated with external beam radiotherapy (RT) using conventional or three-dimensional conformal methods to at least 60 grays (Gy). The median follow-up was 71 months and the median RT dose was 72 Gy (range, Gy). Cox regression models incorporating BF as a time-dependent covariate were used for both univariate and multivariate analyses. Other covariates included in the analyses were T classification, Gleason score, neoadjuvant/adjuvant androgen deprivation, age, RT dose, and pretreatment prostate-specific antigen. RESULTS. BF was observed in 389 men (21%) using the Phoenix definition and 460 men (25%) using the ASTRO definition. DM was observed in 84 patients (5%), 48 patients (3%) patients died of prostate cancer, and 404 patients (22%) died of any cause. The Phoenix definition of BF was found to be a significant predictor of DM, CSM, and OM, after controlling for other significant covariates. The ASTRO definition was found to be associated with CSM and DM, but not OM. CONCLUSIONS. The Phoenix definition of BF is a more robust determinant of patient outcome compared with the ASTRO definition. The correlation with mortality, including OM, and the independence of this correlation from the use of neoadjuvant/adjuvant androgen deprivation, supports the use of Nadir 1 2in prostate cancer clinical trials of RT with or without androgen deprivation. Cancer 2008;112: Ó 2007 American Cancer Society. KEYWORDS: prostate cancer, biochemical failure, definition, survival, radiotherapy. In the late 1990s, the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus guidelines provided a starting point for a uniform definition of biochemical failure (BF) after treatment with radiotherapy alone. 1 However, with greater patient numbers and longer follow-up, several weaknesses have become clear. First, the ASTRO definition backdates BF, causing an artificial early drop and late flattening of Kaplan-Meier curves. These effects contribute to a pronounced dependency on the length of follow-up. 2,3 Second, the ASTRO definition was not, at the time of its recommendation, associated with clinical outcomes. In fact, after its incorporation as an endpoint, evidence of the prediction of overall mortality (OM) remained elusive. 4 8 It was not until 2004 that the ª 2007 American Cancer Society DOI /cncr Published online 29 October 2007 in Wiley InterScience (
2 56 CANCER January 1, 2008 / Volume 112 / Number 1 ASTRO definition, used as a time-dependant variable, was shown to be correlated with OM. 9 Third, ASTRO BF was originally designed as an endpoint for patients treated with external beam radiotherapy alone. Because there is a natural elevation of the prostate-specific antigen (PSA) level after the withdrawal of androgen deprivation (AD), the ASTRO definition will overestimate BF in these patients. 10 It also fails in many cases to account for the PSA bounce phenomenon, which has been well described ; patients treated with brachytherapy have a greater risk of PSA bounce and are more apt to be misclassified using the ASTRO definition. There are other BF definitions that are more accurate predictors of clinical outcome. 14 Recently, many of these were compared in a pooled analysis. 15 The results showed that when BF was described as a 2-ng/mL rise in PSA over the PSA nadir with BF designated as the time the event occurred (at call), the results were more sensitive and specific for clinical failure than the ASTRO definition and avoided its pitfalls. This analysis did not evaluate the correlations between the ASTRO and nadir 1 2ng/mLdefinitions with cause-specific mortality (CSM) or OM. Although the appeal of the nadir 1 2 ng/ml (Nadir 1 2) definition was acknowledged at a consensus conference in 2006, 16 to our knowledge, there is little evidence that this definition is a stronger predictor of mortality. 4 7 Although both the Nadir 1 2 and ASTRO definitions have been shown to predict for overall survival, these studies did not compare the 2 definitions, were based on patients treated with low doses of radiotherapy (<70 grays [Gy] in the majority of cases), and did not include dose in their analyses. 7,9 As a potential surrogate endpoint in clinical trials, it is important that the Nadir + 2 definition be substantiated as a strong correlate of mortality. In the current study, we demonstrate that Nadir + 2 is a robust determinant of distant metastases (DM), CSM, and OM, much more so than the ASTRO BF. MATERIALS AND METHODS Patient Characteristics A total of 1831 patients with pathologically diagnosed prostate cancer who were treated at Fox Chase Cancer Center between 1987 and 2001 were included in our analysis. Postprostatectomy patients as well as those with lymph node-positive disease or evidence of metastasis at the time of presentation were excluded. Patient characteristics are shown in Table 1. The median age of the patients was 69 years (range, years); 231 patients (13%) were aged 60 years, 773 patients (42%) were ages 61 to 70 TABLE 1 Patient Characteristics Characteristic No. of patients Percent T classification T % T % T3/ % Gleason score % % % Age, y < % % > % Treatment modality 3-dimensional conformal % Conventional % Initial hormone treatment Yes % <6 mo % >24 mo % No % Salvage hormone treatment Yes % No % ipsa, ng/ml < % % > % ipsa indicates initial pretreatment prostate-specific antigen level. years, and 827 patients (45%) were aged >71 years. The average initial pretreatment PSA (ipsa) level was 7.1 ng/ml (range, ng/ml). There were 716 patients (41%) with T1 disease, 857 patients (49%) with T2 disease, and 171 patients (10%) with T3/T4 disease. Neoadjuvant, concurrent, and/or adjuvant hormone therapy was used in 291 patients (16%). The median length of AD was 7.69 months (range, months). The Gleason score was 2 to 6 in 1244 patients (68%), 7 in 442 patients (24%), and 8 to 10 in 145 patients (8%). The median follow-up was 71 months (range, months). Radiotherapy Techniques Patients were treated with conventional (81 patients) and 3-dimensional conformal radiotherapy (1750 patients) to a minimum dose of 60 Gy (range, Gy). These methods have been reported previously. 17 The International Commission on Radiation Units and Measurements reference point doses were used. 18 Briefly, patients were simulated and treated in a supine position in a a-cradle cast for immobilization. In general, patients with T1-2AB disease and a Gleason score <7 received treatment to the pros-
3 Phoenix BF and Overall Survival/Abramowitz et al. 57 tate alone. Patients with T2C-T4 disease or a Gleason score of 7 to 10 were treated to a dose of 46 to 50 Gy to the prostate and periprostatic tissues (small pelvic field) followed by a boost to the prostate and seminal vesicles. The dose was prescribed to the 95% isodose line. All patients were treated with 10 to 18 megavolt photons. Patients treated using intensity modulated radiation therapy (IMRT) are not included in this analysis due to the short follow-up. Endpoints and Statistical Analysis The ASTRO definition of BF as 3 consecutive PSA rises after the post-treatment PSA nadir dated at the midpoint between the nadir and the first rise 1 was compared with the Radiation Therapy Oncology Group (RTOG)-ASTRO Phoenix definition (Nadir 1 2). 15,16 DM was confirmed by imaging. CSM was defined as death determined to be due to prostate cancer. All patient data were collected prospectively by a single data manager. Calculations were begun from the completion of radiotherapy. Both definitions of BF were treated as timedependant variables. Therefore, Cox regression models incorporating BF as a time-dependant variable were used for both univariate and multivariate analyses. Covariates included T classification (T1/T2 vs T3/T4), initial hormone treatment (yes vs no), Gleason score (2 6, 7, and 8 10), radiotherapy dose (continuous variable), ipsa (continuous variable), and age (<60 years, years, and >71 years). Kaplan- Meier estimates were calculated from the time of the completion of radiotherapy. Cox regression models and Kaplan-Meier calculations were performed using both definitions of BF. A stepwise model reduction procedure was applied to determine the most parsimonious model. RESULTS Results Using the Nadir 1 2 Definition of BF BF was observed in 389 patients (21%) using the Nadir 1 2 definition. DM occurred in 84 patients (4.6%) and 48 patients (3%) died of prostate cancer. On univariate analysis, the Phoenix definition was found to be a significant predictor of DM, CSM, and OM, with hazards ratios (HR) of 213, 517, and 2.2, respectively (Table 2). Table 3 shows that Nadir 1 2 BF as a timedependant covariate in multivariate analysis was the most significant predictor of DM, CSM, and OM. On multivariate analysis for OM, BF, age, Gleason score, and T classification were all found to significantly increase the HR for death. T classification and Gleason score also were found to be predictive of DM, TABLE 2 Univariate Analyses of Factors Related to DM, CSM, and OM Endpoint Parameter Comparison HR 95% CI P DM Nadir BF Yes vs no <.0001 ASTRO BF Yes vs no <.0001 Pretreatment Continuous <.0001 PSA (Unit/10) variable RT dose Continuous variable T classification T3/T4 vs T1/T <.0001 Hormone therapy No vs yes Gleason score 7 vs <.0001 Gleason score 8 10 vs <.0001 Age, y vs Age, y 70 vs CSM Nadir BF Yes vs no <.0001 ASTRO BF Yes vs no <.0001 Pretreatment Continuous <.0001 PSA (U/10) variable RT dose Continuous variable T classification T3/T4 vs T1/T <.0001 AD No vs yes Gleason score 7 vs Gleason score 8 10 vs <.0001 Age, y vs Age, y 70 vs OM Nadir1 2 Yes vs no <.0001 ASTRO Yes vs no Pretreatment Continuous PSA (U/10) variable RT dose Continuous variable T classification T3/T4 vs T1/T Hormone therapy No vs yes Gleason score 7 vs Gleason score 8 10 vs <.0001 Age, y vs Age, y 70 vs DM indicates distant metastasis; CSM, cause-specific mortality; OM, overall mortality; HR, hazards ratio; 95% CI, 95% confidence interval; BF, biochemical failure; ASTRO, the American Society for Therapeutic Radiology and Oncology; PSA, prostate-specific antigen; RT, radiotherapy; AD, androgen deprivation. CSM, and OM. Age was not found on multivariate analysis to be a predictor of CSM or DM. Pretreatment PSA was not found to be a significant predictor of DM, CSM, or OM. Results Using the ASTRO Definition of BF ASTRO BF was observed in 460 patients (25%). On univariate analysis, the ASTRO definition was found to be predictive of DM (HR of 87) and CSM (HR of 40), but not OM. Table 4 shows the time-dependant multivariate analysis results using the ASTRO BF definition for DM, CSM, and OM. With regard to DM, ASTRO BF was found to be significant, with an HR of 63. Other
4 58 CANCER January 1, 2008 / Volume 112 / Number 1 TABLE 3 Nadir 1 2 Multivariate Analysis of Factors Related to DM, CSM, and OM Endpoint Variable HR 95% CI P DM Nadir <.0001 Gleason score 7 vs Gleason score 8 10 vs T classification T3/T4 vs T1/T CSM Nadir <.0001 Gleason score 7 vs Gleason score 8 10 vs T classification T3/T4 vs T1/T OM Nadir <.0001 Age y vs 60 y Age 70 y vs 60 y <.0001 Gleason score 7 vs Gleason score T classification T3/T4 vs T1/T DM indicates distant metastasis; CSM, cause-specific mortality; OM, overall mortality; HR, hazards ratio; 95% CI, 95% confidence interval. significant covariates were Gleason score and T classification. For CSM, ASTRO BF was found to be a significant predictor, with an HR of 26. Other factors that were found to be predictive for CSM were ipsa, T classification, and Gleason score. The ASTRO definition was not found to be an independent predictor of OM (HR of 1.0). Factors that did predict for OM were age, ipsa, Gleason score, T classification, and radiotherapy dose. TABLE 4 ASTRO Multivariate Analysis for DM, CSM, and OM Endpoint Variable HR 95% CI P DM ASTRO BF <.0001 Gleason score Gleason score T classification T3/T CSM ASTRO BF <.0001 Pretreatment PSA (Unit/10) Gleason score 7 vs Gleason score 8 10 vs T classification T3/T4 vs T1/T <.001 OM ASTRO BF Age y vs 60 y Age 70 y vs 60 y <.0001 Pretreatment PSA (U/10) Gleason score 7 vs Gleason score 8 10 vs <.0001 T classification T3/T4 vs T1/T <.02 RT dose (Gy) ASTRO indicates the American Society for Therapeutic Radiology and Oncology; DM, distant metastasis; CSM, cause-specific mortality; OM, overall mortality; HR, hazards ratio; 95% CI, 95% confidence interval; BF, biochemical failure; PSA, prostate-specific antigen; RT, radiotherapy; Gy, grays. DISCUSSION The ASTRO definition was the first consensus definition of PSA failure that promoted the standardization of analyses between institutions. However, several shortcomings have been recognized, including the artificial flattening of Kaplan-Meier curves and confounding bias from the length of follow-up. The Phoenix BF definition minimizes these problems and more accurately classifies BF in the setting of AD. 15,19 There is a limited experience with Nadir 1 2 BF, particularly in terms of how this definition relates to mortality. This is especially true in patients treated with contemporary doses of radiotherapy. In the current study, the Nadir 1 2 definition was found to be the strongest determinant of DM, CSM, and OM after adjusting for the conventional clinical factors of ipsa and Gleason score end stage, as well as radiotherapy dose and the use of neoadjuvant/adjuvant AD. The correlation between Nadir 1 2 definition and OM was notably robust, especially when considering that ASTRO BF definition was not associated with OM. Although the ASTRO BF definition has been found to predict for OM, 9 this correlation has been observed inconsistently. 4 7 The current study is not the first to compare the ASTRO and Phoenix definitions. 7,20 However, to our knowledge, this is the first time the Phoenix definition has been shown to be superior to the ASTRO definition for these endpoints. The study by Kwan et al. was the first study to demonstrate that the Phoenix definition predicts for OS. This study did not discuss the pros and cons of various definitions for BF. 7 In addition, the current study was the first study to show this using high-dose radiotherapy. This is noteworthy given the dose effects DM and BF rates. 21 The ASTRO definition previously has been shown to be inferior to other definitions by Kuban et al. and more recently in a pooled analysis by Horwitz et al. 15,22 In the latter study, the ASTRO and Phoenix definitions as well as multiple other definitions of BF were compared. Horwitz et al. concluded that the Nadir 1 2 definition was the preferable definition given its simplicity, sensitivity, and sensitivity. However, survival endpoints were not evaluated in these studies. The consensus conference statement from the RTOG-ASTRO has furthered this opinion. The Phoenix conference recommendation was for the Nadir 1 2 definition to be accepted as the current standard. They further recommend that use of the
5 Phoenix BF and Overall Survival/Abramowitz et al. 59 ASTRO consensus definition be considered inappropriate if AD is used. 16 The results of the current study demonstrate that prostate cancer recurrence or death due to prostate cancer was extremely uncommon without BF using either definition. The robust HRs noted in the current study are consistent with other published results. 8,23,24 However, in these other studies, including the one by Pollack et al., 8 a profound correlation between BF and OM using the ASTRO definition was found to be marginal at best. The benefit of AD in high-risk prostate cancer patients is well known. It is interesting that this therapy was not found to be predictive for outcome. Because the use of salvage AD was defined as a failure in both definitions, this would not affect our results. The percentage of patients in the current study who were treated with AD was also low, which would make our ability to detect statistical significance on multivariate analysis poor. Finally, the majority of these patients were treated with doseescalated radiotherapy, in which the benefits of AD are less well known. The current study contrasts the ability of the Phoenix and ASTRO definitions to predict clinical outcomes and survival in patients with prostate cancer. Based on the current study results, it is clear that the Nadir 1 2 definition is a superior predictor of DM, CSM, and OM. This is especially important when trying to asses the impact of treatment modalities on a disease with a long natural history in a clinical trial. The Phoenix definition is a superior endpoint for use in clinical trials and also may be of use in discussions with patients. Conclusions The results of the current study demonstrate that the Phoenix definition of BF is an early predictor of OM, CSM, and metastatic disease. It is superior to the ASTRO definition with regard to these endpoints. REFERENCES 1. Cox J, Grignon D, Kaplan R, Parsons J, Schellhammer P. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37: Horwitz EM, Uzzo RG, Hanlon AL, Greenberg RE, Hanks GE, Pollack A. Modifying the ASTRO definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3D conformal radiation therapy alone. J Urol. 2003;169: Vicini F, Kestin L, Martinez A. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45: Horwitz E, Vicini F, Ziaja E, Dmuchowski C, Stromberg J, Martinez A. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys. 1998;41: Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specificantigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000;48: Kupelian PA, Buchsbaum JC, Patel C, et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys. 2002;52: Kwan W, Pickles T, Duncan G, et al. PSA failure and the risk of death in prostate cancer patients treated with radiotherapy.[see comment]. Int J Radiat Oncol Biol Phys. 2004;60: Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57: Williams SG, Duchesne GM, Millar JL, Pratt GR. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60: Buyyounouski MK, Hanlon AL, Eisenberg DF, et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys. 2005;63: Rosser CJ, Kuban DA, Levy LB, et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol. 2002;168: Hanlon AL, Pinover WH, Horwitz EM, Hanks GE. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys. 2001;50: Horwitz EM, Levy LB, Thames HD, et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer. 2006;107: Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and Int J Radiat Oncol Biol Phys. 2003;57: Horwitz EM, Thames HD, Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol. 2005;173: Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65: Corn BW, Hanks GE, Schultheiss TE, Hunt MA, Lee WR, Coia LR. Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. Int J Radiat Oncol Biol Phys. 1995;32:
6 60 CANCER January 1, 2008 / Volume 112 / Number Monti AF, Ostinelli A, Frigerio M, et al. An ICRU 50 radiotherapy treatment chart. Radiother Oncol. 1995;35: Taylor JM, Griffith KA, Sandler HM. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50: Johnstone PA, Williams SR, Riffenburgh RH. The 100-day PSA: usefulness as surrogate end point for biochemical disease-free survival after definitive radiotherapy of prostate cancer. Prostate Cancer Prostatic Dis. 2004;7: Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys. 2007;68: Kuban DA, Thames HD, Levy LB, et al. Failure definition-dependent differences in outcome following radiation for localized prostate cancer. can one size fit all? Int J Radiat Oncol Biol Phys. 2003;57(2 suppl):s146 S Vicini FA, Kestin LL, Martinez AA. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. [see comment]. Cancer. 2000;88: Kestin LL, Vicini FA, Martinez AA. Practical application of biochemical failure definitions: what to do and when to do it. Int J Radiat Oncol Biol Phys. 2002;53:
Radiation dose has been reported to be an important determinant
538 The Relationship of Increasing Radiotherapy Dose to Reduced Distant Metastases and Mortality in Men with Prostate Cancer Rojymon Jacob, M.D. 1 Alexandra L. Hanlon, Ph.D. 2 Eric M. Horwitz, M.D. 1 Benjamin
More informationSupported by M. D. Anderson Cancer Center physician investigator funds. We thank Gerald E. Hanks, MD, for help and guidance with this project.
1496 Biochemical and Clinical Significance of the Posttreatment Prostate-Specific Antigen Bounce for Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone A Multiinstitutional Pooled
More informationVol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationPSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up
Original article Original articles PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up Roman Makarewicz, MD, PhD, Prof., Andrzej
More informationJure Murgic 1, Matthew H Stenmark 1, Schuyler Halverson 1, Kevin Blas 1, Felix Y Feng 1,2 and Daniel A Hamstra 1,3*
Murgic et al. Radiation Oncology 2012, 7:127 RESEARCH Open Access The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for
More informationRadiation treatment in prostate cancer : balancing between tumor control and toxicity Heemsbergen, W.D.
UvA-DARE (Digital Academic Repository) Radiation treatment in prostate cancer : balancing between tumor control and toxicity Heemsbergen, W.D. Link to publication Citation for published version (APA):
More informationBiochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy
Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir October 2015, Volume: 7, Issue: 6, Pages: 1330-1335, DOI: 10.14661/1330 Biochemical progression-free survival in localized prostate cancer
More informationImpact of the duration of hormonal therapy following radiotherapy for localized prostate cancer
ONCOLOGY LETTERS 10: 255-259, 2015 Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer MITSURU OKUBO, HIDETUGU NAKAYAMA, TOMOHIRO ITONAGA, YU TAJIMA, SACHIKA
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationUpdated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy for Locally and Locally Advanced
Clinical Urology High-Dose Rate Brachytherapy for Prostate Cancer International Braz J Urol Vol. 34 (3): 293-301, May - June, 2008 Updated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy
More informationHeterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
More informationComparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend
More informationHIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER
0022-5347/01/1663-0876/0 THE JOURNAL OF UROLOGY Vol. 166, 876 881, September 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED
More informationProject approved by the Fondo de investigaciones Socio Sanitarias (FISS). Resolution dated June 8, Official State Gazette: June 17, 2004.
Edition No. 01 Phase III randomized and multicenter trial of adjuvant androgen deprivation combined with high-dose 3-dimensional conformal radiotherapy in intermediate- or high-risk localized prostate
More informationdoi: /j.ijrobp CLINICAL INVESTIGATION
doi:10.1016/j.ijrobp.2006.04.029 Int. J. Radiation Oncology Biol. Phys., Vol. 65, No. 4, pp. 965 974, 2006 Copyright 2006 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/06/$ see front
More informationClinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer
Original Article Radiat Oncol J 205;33():2-28 http://dx.doi.org/0.3857/roj.205.33..2 pissn 2234-900 eissn 2234-356 Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation
More informationdoi: /j.ijrobp CLINICAL INVESTIGATION
CME doi:10.1016/j.ijrobp.2010.07.2004 Int. J. Radiation Oncology Biol. Phys., Vol. 81, No. 5, pp. 1293 1301, 2011 Copyright Ó 2011 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see
More informationdoi: /s (03) CLINICAL INVESTIGATION
doi:10.1016/s0360-3016(03)01746-2 Int. J. Radiation Oncology Biol. Phys., Vol. 58, No. 4, pp. 1048 1055, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access Prostate- specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low- dose- rate brachytherapy
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 28 OCTOBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Predictors of Prostate Cancer Specific Mortality After Radical Prostatectomy or Radiation Therapy Ping Zhou,
More informationProstate Cancer. 3DCRT vs IMRT : Hasan Murshed
Prostate Cancer 3DCRT vs IMRT : the second debate Hasan Murshed Take home message IMRT allows dose escalation. Preliminary data shows IMRT technique improves cancer control while keeping acceptable morbidity
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationOriginal Article. Cancer September 15,
Gleason Pattern 5 Is the Strongest Pathologic Predictor of Recurrence, Metastasis, and Prostate Cancer-Specific Death in Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy William
More informationUPDATE OF DUTCH MULTICENTER DOSE-ESCALATION TRIAL OF RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER
doi:1.116/j.ijrobp.28.2.73 Int. J. Radiation Oncology Biol. Phys., Vol. 72, o. 4, pp. 98 988, 28 Copyright Ó 28 Elsevier Inc. Printed in the USA. All rights reserved 36-316/8/$ see front matter CLIICAL
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationNIH Public Access Author Manuscript Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2012 June 1.
NIH Public Access Author Manuscript Published in final edited form as: Int J Radiat Oncol Biol Phys. 2011 June 1; 80(2): 445 452. doi:10.1016/j.ijrobp.2010.02.034. Impact of ultrahigh baseline PSA levels
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 4 FEBRUARY 1 28 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate
More informationfailure (FBF) rates were calculated using the Phoenix definition.
. JOURNAL COMPILATION 2009 BJU INTERNATIONAL Urological Oncology GLEASON SCORES 8 10 PROSTATE CANCER TREATED WITH TRIMODAL THERAPY STOCK et al. BJUI BJU INTERNATIONAL Outcomes for patients with high-grade
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationA comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer
ORIGINAL RESEARCH A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer Daniel Taussky, MD; 1 Véronique Ouellet, MD; 2 Guila Delouya,
More informationTanaka et al. BMC Urology 2012, 12:28
Tanaka et al. BMC Urology 2012, 12:28 RESEARCH ARTICLE Open Access Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent
More informationGenitourinary Cancer. When Prostate Brachytherapy Fails: A Case Report and Discussion. The Oncologist 2005;10:
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Genitourinary Cancer When Prostate Brachytherapy Fails: A Case
More informationTITLE: Hierarchical Nonlinear Mixed Effects Modeling: Defining Post-Radiation Therapy Relapse in Prostate Cancer Patients
AD Award Number: DAMD17-01-1-0056 TITLE: Hierarchical Nonlinear Mixed Effects Modeling: Defining Post-Radiation Therapy Relapse in Prostate Cancer Patients PRINCIPAL INVESTIGATOR: Alexandra L. Hanlon,
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationAndrew K. Lee, MD, MPH Associate Professor Department tof fradiation Oncology M.D. Anderson Cancer Center
Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Associate Professor Department tof fradiation Oncology M.D. Anderson Cancer Center Seungtaek Choi, MD Assistant Professor Department tof fradiation
More informationMichelle S Ludwig 1*, Deborah A Kuban 2, Xianglin L Du 4, David S Lopez 4, Jose-Miguel Yamal 5 and Sara S Strom 3
Ludwig et al. BMC Cancer (2015) 15:190 DOI 10.1186/s12885-015-1180-6 RESEARCH ARTICLE Open Access The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk
More informationdiagnosed by transrectal needle biopsy who completed 3DCRT alone be- Center, Philadelphia, Pennsylvania.
75 Evidence of Increased Failure in the Treatment of Prostate Carcinoma Patients Who Have Perineural Invasion Treated with Three-Dimensional Conformal Radiation Therapy Steven R. Bonin, M.D. 1 BACKGROUND.
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More informationRadiation Dose Escalation for Localized Prostate Cancer
Radiation Dose Escalation for Localized Prostate Cancer Intensity-Modulated Radiotherapy Versus Permanent Transperineal Brachytherapy William W. Wong, MD 1 ; Sujay A. Vora, MD 1 ; Steven E. Schild, MD
More informationPROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER
PROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER Alberto Bossi Radiotherapy and Oncology Gustave Roussy, Villejuif, France PROSTATE CANCER, Radiotherapy IGRT RT + ADT: short vs
More informationPSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationThe use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials
British Journal of Cancer (2004) 90, 950 954 All rights reserved 0007 0920/04 $25.00 www.bjcancer.com Minireview The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationPORT after RP. Adjuvant. Salvage
PORT after RP Adjuvant Or Salvage RT after RP 40-50% PSA relapse after RP in HR Definition: PSA should be undetectable within 6 weeks of RP Initial PSA is measured 6-12 weeks after RP AUA defines biochemical
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationSRO Tutorial: Prostate Cancer Clinics
SRO Tutorial: Prostate Cancer Clinics May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible, and
More informationTREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME
ADULT UROLOGY TREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME VIBHA BHATNAGAR, SUSAN T. STEWART, WILLIAM W. BONNEY, AND ROBERT M. KAPLAN ABSTRACT
More informationProstate cancer: Update from the BCCA
Prostate cancer: Update from the BCCA Tom Pickles Clinical Professor, UBC Topics 1. Incidence & Utilization rates 2. New developments with External Beam RT IGRT, VMAT and other enhancements Optimizing
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationIntensity Modulated Radiotherapy (IMRT) of the Prostate
Medical Policy Manual Medicine, Policy No. 137 Intensity Modulated Radiotherapy (IMRT) of the Prostate Next Review: August 2018 Last Review: November 2017 Effective: December 1, 2017 IMPORTANT REMINDER
More informationErectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
More informationRadiotherapy (RT) Protocol for Prostate Cancer
Radiotherapy (RT) Protocol for Prostate Cancer CGMH-2010-02 *This document is aimed to set up RT protocols for prostate cancer. The treatment guideline for prostate cancer will not be covered here. A.
More informationCorey C Foster 1, William C Jackson 1, Benjamin C Foster 1, Skyler B Johnson 1, Felix Y Feng 1 and Daniel A Hamstra 1,2*
Foster et al. Radiation Oncology 2014, 9:245 RESEARCH Open Access Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical
More informationBJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent
21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for
More informationMonotherapy with Carbon Ion Radiation for Localized Prostate Cancer
Japanese Journal of Clinical Oncology Advance Access published May 30, 2006 Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer Jun Shimazaki 1, Koichiro Akakura 1, Hiroyoshi Suzuki 1,
More informationTanaka et al. BMC Cancer (2017) 17:573 DOI /s
Tanaka et al. BMC Cancer (2017) 17:573 DOI 10.1186/s12885-017-3565-1 RESEARCH ARTICLE Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationRadiotherapy for Localized Hormone-refractory Prostate Cancer in Japan
Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan KATSUMASA NAKAMURA 1, TERUKI TESHIMA 2, YUTAKA TAKAHASHI 2, ATSUSHI IMAI 3, MASAHIKO KOIZUMI 4, NORIO MITSUHASHI 5, YOSHIYUKI SHIOYAMA
More informationDepartment of Radiotherapy & Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt.
Original article Res. Oncol. Vol. 12, No. 1, Jun. 2016:10-14 Dosimetric comparison of 3D conformal conventional radiotherapy versus intensity-modulated radiation therapy both in conventional and high dose
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationRadical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationWould SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy?
Would SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy? Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan Disclosure
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More information55 th Annual Meeting American Society for Radiation Oncology. Patients: Hope Guide Heal News Briefing
55 th Annual Meeting American Society for Radiation Oncology Patients: Hope Guide Heal News Briefing Sunday, September 22, 2013 4:45 p.m. 5:15 p.m. Colleen A.F. Lawton, MD, FASTRO 2013 ASTRO President
More informationAmerican Urological Association (AUA) Guideline
1 (AUA) Guideline Approved by the AUA Board of Directors April 2013 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2013 by the American
More informationANTICANCER RESEARCH 26: (2006)
Low Pre-radiotherapy Prostate-specific Antigen Level is a Significant Predictor of Treatment Success for Postoperative Radiotherapy in Patients with Prostate Cancer TOMONARI SASAKI 1, KATSUMASA NAKAMURA
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationTreatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer Nobukazu Fuwa 1, Akinori Takada 2 and Takahiro Kato 3 1;Departments of Radiology, Hyogo Ion Beam Medical
More informationLong-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer focus on overall survival
Freiberger et al. Radiation Oncology (2017) 12:98 DOI 10.1186/s13014-017-0837-5 RESEARCH Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer focus
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationDOSE ESCALATION USING CONFORMAL HIGH-DOSE-RATE BRACHYTHERAPY IMPROVES OUTCOME IN UNFAVORABLE PROSTATE CANCER
PII S0360-3016(02)02733-5 Int. J. Radiation Oncology Biol. Phys., Vol. 53, No. 2, pp. 316 327, 2002 Copyright 2002 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/02/$ see front
More informationORIGINAL INVESTIGATION. Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans. having prostate cancer, assessment
ORIGINAL INVESTIGATION Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans Edward M. Uchio, MD; Mihaela Aslan, PhD; Carolyn K. Wells, MPH; Juan Calderone, MD; John Concato, MD, MS, MPH
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationRadiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices
Original original research Radiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices Michel Zimmermann, MD; * Daniel Taussky,
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationSalvage Brachytherapy After External-Beam Irradiation for Prostate Cancer
Salvage Brachytherapy After External-Beam Irradiation for Prostate Cancer Review Article [1] February 01, 2004 By David C. Beyer, MD [2] The options available for patients with recurrent prostate cancer
More informationThe Use of Conformal Radiotherapy and the Selection of Radiation Dose in T1 or T2 Prostate Cancer
Evidence-based Series 3-11 EDUCATION AND INFORMATION 2011 The Use of Conformal Radiotherapy and the Selection of Radiation Dose in T1 or T2 Prostate Cancer Members of the Genitourinary Cancer Disease Site
More informationLewis Garvey Smith III, MD Reference List
Journal D'Souza WD, Lee HK, Palmer MB, Smith LG, Pollack A. Is intraoperative nomogram-based overplanning of prostate implants necessary? Int J Radiat.Oncol.Biol.Phys. 56[2], 462-467. 2003 Rosser CJ, Chichakli
More information